Topics

Aurora Kinase C Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

22:35 EST 3 Feb 2020 | BioPortfolio Reports

Aurora Kinase C Pipeline Review, H2 2019


Summary


According to the recently published report 'Aurora Kinase C Pipeline Review, H2 2019'; Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.


Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 Aurora Kinase C is a member of the Aurora subfamily of serine/threonine protein kinases. Aurora Kinase C is a chromosomal passenger protein that forms complexes with AuroraB and inner centromere proteins and plays an important role in organizing microtubules in relation to centrosome function during mitosis. It is over expressed in several cancer cell lines and involved in oncogenic signal transduction.


The report 'Aurora Kinase C Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Ovarian Cancer, Solid Tumor, Breast Cancer, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, NonSmall Cell Lung Cancer, Peripheral TCell Lymphomas PTCL, Prostate Cancer and TripleNegative Breast Cancer TNBC.


Scope


The report provides a snapshot of the global therapeutic landscape for Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1

The report reviews Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase C Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Aurora Kinase C Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Aurora Kinase C Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...